Marvel Biosciences grants 50,001 deferred share units to independent directors in lieu of cash fees

• Marvel Biosciences granted 50,001 deferred share units to its three independent directors in lieu of cash directors’ fees.
• All DSUs vest on Sept. 1, 2027; settlement occurs on each director’s separation from service.
• Deemed value set using Aug. 31, 2026 VWAP of $0.15 per common share on the TSX Venture Exchange.
• Units expire 365 days after a director’s separation from service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609011701NEWSFILECNPR____20260901_312429_1) on September 01, 2026, and is solely responsible for the information contained therein.